FDA Removes 12 Peptides from Category 2: BPC-157, TB-500, Semax, and More No Longer Flagged as Safety Risks

On April 15, 2026, the FDA published an update to its Section 503A bulk drug substances categories, announcing the removal of 12 peptide-based compounds from Category 2. Category 2 is the FDA’s list of bulk drug substances that the agency has determined “may present significant safety risks” when used in compounding — effectively a ban on their use by compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The removal affects twelve peptides that have been at the center of a contentious regulatory battle between the FDA, compounding pharmacies, peptide therapy practitioners, and political figures: BPC-157, TB-500, Semax, MOTS-c, GHK-Cu (injectable formulations only), Epitalon, LL-37, DiHexa, DSIP (delta sleep-inducing peptide/emideltide), KPV, PEG-MGF, and Melanotan II.

The FDA stated that the removals are occurring because the original nominations that placed these substances on the Category 2 list were withdrawn by the nominators. The effective date is seven calendar days from publication — approximately April 22, 2026.

This is the most significant regulatory shift in peptide therapy access since the FDA began its compounding crackdown in 2023. However, what the removal means in practice is more nuanced than the headlines suggest.

The regulatory distinction here is critical and has been widely misunderstood in the peptide therapy community.

What removal from Category 2 means. These 12 peptides are no longer designated as substances that “may present significant safety risks.” The FDA is no longer actively categorizing them as dangerous for compounding purposes. This is a meaningful regulatory signal — it suggests the agency’s position on these compounds has shifted.

What removal does NOT mean. Removal from Category 2 does not place these substances on the 503A bulks list (sometimes called Category 1 or the “approved for compounding” list). It does not authorize compounding pharmacies to immediately begin producing these peptides. It does not constitute FDA approval of these substances for any therapeutic use. And it does not create a new legal pathway for purchasing or using these peptides outside of existing regulations.

The regulatory gray area. After removal, these 12 peptides exist in an unusual regulatory space: they are no longer flagged as safety concerns, but they are not yet authorized for compounding. The FDA has indicated that each substance will go through PCAC review before a final determination is made about whether it can be added to the 503A bulks list. Until that process is complete, the legal status of compounding these peptides is ambiguous.

Some compounding pharmacies may interpret the removal as permission to resume production. Others will wait for explicit PCAC recommendation and FDA action. Patients should understand that this regulatory ambiguity means access and legal status may vary by state and by pharmacy.

For context, here is a brief overview of each affected compound and its primary research or clinical interest.

BPC-157 (Body Protection Compound-157). A synthetic peptide derived from a gastric protein. Widely used in the peptide therapy community for tissue healing, joint repair, and gut health. Extensive animal research but no completed human clinical trials.

TB-500 (Thymosin Beta-4 fragment). A fragment of thymosin beta-4 used for injury recovery, tissue repair, and inflammation reduction. Animal data is promising; human clinical data is limited.

Semax. A synthetic peptide based on ACTH (adrenocorticotropic hormone). Used as a nootropic for cognitive enhancement, neuroprotection, and anxiety reduction. Approved in Russia as a prescription medication but not FDA-approved in the United States.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c). A mitochondrial-derived peptide involved in metabolic regulation and exercise mimetic effects. Research interest in aging, insulin sensitivity, and metabolic health.

GHK-Cu (injectable formulations only). A copper-binding tripeptide with research applications in wound healing, skin rejuvenation, and anti-inflammatory effects. Topical GHK-Cu products are unaffected by this regulatory change — only injectable formulations were on Category 2.

Epitalon (Epithalamin). A synthetic tetrapeptide studied for telomerase activation and potential anti-aging properties. Limited human data; most evidence comes from animal studies.

LL-37 (Cathelicidin). An antimicrobial peptide involved in innate immune defense. Research interest in infection resistance and immune modulation.

DiHexa (Dihexa Acetate). A synthetic hexapeptide studied for cognitive enhancement and potential neuroprotective effects. Early-stage research with limited human data.

DSIP (Delta Sleep-Inducing Peptide/Emideltide). A neuropeptide studied for sleep regulation and stress reduction. Named for its original discovery context but its sleep-inducing mechanism is not fully characterized.

KPV. A tripeptide fragment of alpha-MSH with anti-inflammatory properties. Research interest in gut inflammation and mucosal healing.

PEG-MGF (Pegylated Mechano Growth Factor). A pegylated form of a growth factor splice variant. Used in the bodybuilding and recovery community; limited clinical research.

Melanotan II. A synthetic peptide that stimulates melanocortin receptors. Known for tanning and sexual function effects. Carries more established safety concerns than most peptides on this list, including cardiovascular risks and nevi (mole) changes.

The FDA has scheduled Pharmacy Compounding Advisory Committee (PCAC) meetings to formally evaluate these peptides for potential inclusion on the 503A bulks list. The timeline is staggered.

July 23, 2026: PCAC will review BPC-157, KPV, MOTS-c, and TB-500. These are the four most widely used peptides on the list and the ones with the highest patient demand.

July 24, 2026: PCAC will review Emideltide (DSIP), Epitalon, and Semax (all in acetate and free base forms).

Early 2027: Additional PCAC meetings will cover Cathelicidin LL-37, Dihexa Acetate, GHK-Cu (all routes of administration), PEG-MGF, and Melanotan II.

What PCAC review involves. The committee evaluates available safety data, evidence of therapeutic benefit, the existence (or absence) of approved drug alternatives, and potential public health risks. Nominations typically include a dossier of published research, proposed compounding standards, and safety arguments. The committee issues a recommendation — either supporting or opposing inclusion on the 503A list — which the FDA then considers in making its final determination.

What a positive recommendation means. A favorable PCAC recommendation does not guarantee FDA action, but historically the agency has generally followed PCAC guidance. If the PCAC recommends inclusion, the FDA could move relatively quickly to add these substances to the 503A list, formally authorizing their compounding.

The most closely watched votes will be BPC-157 and TB-500 — the two most commonly prescribed peptides affected by the Category 2 restrictions. A positive PCAC recommendation for these compounds would effectively end the two-year regulatory freeze on the most popular healing peptides in clinical use.

This regulatory shift did not happen in a vacuum. The removal of these 12 peptides from Category 2 follows months of political pressure that has reshaped the FDA’s approach to peptide regulation.

The FDA’s original position. Beginning in 2023, the FDA moved aggressively to restrict compounded peptide access by placing numerous peptide substances on the Category 2 list. The agency’s stated rationale was that these compounds lacked sufficient safety data for compounding use and that their widespread availability through compounding pharmacies posed public health risks.

RFK Jr.’s intervention. In early 2026, HHS Secretary Robert F. Kennedy Jr. publicly called for the reclassification of peptides and expanded patient access. His position — that the FDA had been overly restrictive and that patients should have access to peptide therapies through licensed compounding pharmacies — directly challenged the agency’s regulatory approach. In March 2026, the FDA reclassified 14 peptides under political pressure.

The April 2026 removals. The removal of 12 additional peptides from Category 2 continues this trend. The FDA’s stated reason — that nominations were withdrawn by nominators — is procedurally accurate but occurs within a political environment where the agency is under significant pressure to soften its peptide restrictions.

What this means for patients. The political context matters because it suggests the regulatory trajectory is toward greater peptide access, not less. The scheduling of PCAC meetings for July 2026 indicates the FDA is moving toward formal determinations rather than maintaining the status quo. Patients should interpret this as a positive signal while understanding that the regulatory process is not yet complete.

For patients who have been using or are interested in the 12 affected peptides, here is practical guidance based on the current regulatory situation.

Do not assume these peptides are fully legal to compound. The Category 2 removal is a significant step but not the final one. Until PCAC review is complete and the FDA takes formal action, the legal status of compounding these substances is uncertain. Reputable compounding pharmacies will be cautious about resuming production without clearer regulatory authorization.

Watch for PCAC meeting outcomes in July 2026. The July 23–24 meetings will cover the most important peptides: BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax. The committee’s recommendations will be the strongest signal yet about whether these peptides will be formally authorized for compounding.

Work with licensed healthcare providers. Regardless of regulatory status, peptide therapy should be supervised by a qualified healthcare provider who can assess appropriateness, monitor for adverse effects, and ensure proper dosing. The regulatory changes do not change the medical reality that these compounds have limited human clinical data.

Be cautious about gray-market sources. The regulatory transition period may create confusion that gray-market suppliers exploit. Products sold as “research peptides” or through unregulated online channels do not have the quality controls of licensed compounding pharmacies. Patients should prioritize sourcing from licensed pharmacies once compounding is formally authorized.

Understand that Category 2 removal does not equal safety validation. The FDA removing these peptides from the “significant safety concerns” list does not mean the agency has determined they are safe and effective. It means the specific regulatory mechanism (Category 2 nomination) is being withdrawn. Safety and efficacy determinations for each compound remain ongoing.